Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $106.93M | $2.45 | Not rated | -5.3 | +25.62% |
Nutriband Inc. NASDAQ:NTRB | $67.95M | $5.59 | Not rated | -1.8 | -0.79% |
Fortress Biotech, Inc. NASDAQ:FBIO | $60.70M | $1.82 | Undervalued | 0.7 | -30.04% |
Adagene Inc. NASDAQ:ADAG | $55.72M | $1.48 | Not rated | -7.9 | +13.56% |
XBiotech Inc. NASDAQ:XBIT | $54.27M | $1.78 | Not rated | -1.8 | -24.32% |
OS Therapies Incorporated AMEX:OSTX | $34.86M | $0.74 | Not rated | -2.0 | -29.01% |
Adicet Bio, Inc. NASDAQ:ACET | $26.03M | $2.78 | Overvalued | -0.8 | -40.15% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $9.59M | $0.15 | Not rated | -1.0 | -16.29% |
Continue the stock analysis
Jump to another research area for this company.